Atopic Dermatitis Clinical Trial
Official title:
Antipruritic Effect of Acupuncture in Patients With Atopic Dermatitis: Feasibility Study Protocol for a Randomised, Sham-Controlled Trial.
Introduction: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease
inducing poor quality of life. Its conventional treatments often cause unsatisfactory relief
and adverse effects in long-term application. Acupuncture treatment is regarded to have a
curative effect on AD symptoms. The aim of this trial is to evaluate the therapeutic effects
of acupuncture on AD symptoms including pruritus and poor quality of life in patients with
AD.
Method and Analysis: This trial is a randomized, sham-controlled pilot trial with different
visit frequencies. 30 eligible patients with atopic dermatitis will be randomly allocated in
a ratio of 1:1:1 to the Verum Acupuncture group 1 (VA1, 3 days weekly), Verum Acupuncture
group 2 (VA2, 2 days weekly) and Sham Acupuncture group (2 days weekly). The acupuncture
treatment will be given three or two times a week for 4 weeks according to the allocated
groups. The main outcome measures are Visual analogue scale for itch (itch VAS), SCORing
Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) to evaluate the
improvement of AD symptoms and Patient Oriented Eczema Measure (POEM), Dermatology Life
Quality Index (DLQI) to assess the quality of life of AD patients. It will be measured at
baseline, once a week during treatment period and after follow-up period.
Ethics/Dissemination: This protocol was approved by the Institutional Review Boards at Kyung
Hee University Korean Medicine Hospital on May 2016. The permission number is
KOMCIRB-160212-HRBR-004. This trial will provide the data of therapeutic effects of treating
atopic dermatitis with acupuncture in accordance with the different visit frequencies. The
outcomes will be facilitated to calculate the sample size of further study with the same
design of this study. The findings from this trial will be published and presented in
conference.
Objectives This pilot study aims to investigate the feasibility of validating the
anti-pruritic effectiveness of the sole acupuncture intervention and the efficacy of
different frequent treatments of acupuncture, and discovering noble candidates of a specific
biomaterial associated with the development of atopic dermatitis. Moreover, the result will
be facilitated in calculating the sample size on the further study.
Trial design A randomized, sham-controlled, different intervention frequency trial will be
conducted at the Kyung Hee University Korean Medicine Hospital from June to November 2016.
Participants and Recruitment
Recruitment Acquiring consent will be conducted by the investigators with the principle of
informed consent which confirms participants' voluntarism. The participants will sign the
document made of general consent form and additional consent provisions for blood collection
and use of their human derived material first of all. The exemplary consent paper and other
related literature can be offered upon request.
Randomization and allocation concealment The AD patients will be randomized to one of the
three groups via block randomization.
An independent statistician will product random numbers with the PROC PLAN of SAS 9.2 (SAS
institute Inc., Cary, NC, USA) and transfer them to the Acupuncture and Meridian Science
Research Center (AMSRC) at Kyung Hee University where the each randomization number will be
sealed in a sequentially numbered non-transparent envelope by a staff uninvolved in this
study.
At the beginning of the randomization process, the investigator will call the independent
staff in AMSRC to pass the screening number of the participant. Then the AMSRC staff
immediately assign the participating patient to one of three groups by unsealing a numbered
envelope. It will be documented in the trial master file thoroughly.
Blinding The participating patients and the assessor will be blinded to the group allocation
of patients in this trial. It is impossible for acupuncturists to be unaware of the group
assignments, but they will not perform the outcome measurements or data analyses.
To prevent a possible bias, the eye patch will be applied for the patients during the
acupuncture treatment, and they will be unable to see the practice procedures. All the
acupuncture treatment, regardless of the group assignment, will be practiced by using Park
sham devices (AcuPrime Co., Ltd., Exeter, UK) which is attached on the applied acupoints as
to block the sighting of penetrating or non-penetrating on the skin of acupuncture needles 9.
The acupuncture needles and devices will be maintained for 15 min identically.
Intervention Acupuncture treatment Both manual acupuncture treatment and acupressure would be
conducted on every participating AD patient. It was designed to become a pragmatic treatment
procedure corresponding with real clinic settings.
In this study, the manual acupuncture treatment is composed of basic acupuncture treatment
and additional acupuncture treatment: partially individualized acupuncture treatment will be
conducted on the basis of the traditional meridian theory and consensus by the experts in
acupuncture and the atopic disease. The number of applied acupoints per patient per session
ranges from 6 to 19. The optional points include ST43, GB41, LI2, TE3, SI3, TE6, SI2, BL66,
LR3 and SP3.
The clinical research coordinator will ask the symptoms associated with additional
acupuncture treatment to reduce the bias. The acupuncture treatment will be practiced with a
sterilized stainless needle (40 mm length and 0.25 mm diameter; Dongbang Acupuncture Inc.,
Bundang, Sungnam, Korea) by one same Korean Medicine Docter. Manipulation technique will be
performed to elicit 'de qi' sensation. The needle will be inserted in depth of 5 to 30 mm and
retained for 15 minute.
Acupressure technique will be taken after the elimination of stainless needles. The 1.5 mm
press tack needles (Haeng Lim Seo Won Medical co., China) will be attached on four acupoints
per participating patient per session: LI11 bilaterally and auricular-Shenmen
contralaterally. It was designed with the traditional meridian theory and consensus by the
experts in acupuncture and the atopic disease. The patients will be instructed by the
involved staff to press the applied press tack needles located on LI11 when they feel severe
pruritus for 3 min.
All the acupuncture practice will be carried out by the same Korean Medicine Doctor, who will
be trained for 10 hours to guarantee that he could perform the identical acupuncture
treatment according to the pre-constructed protocol.
Dropout criteria on patients' visits During the study period, each patient will visit 12 or 8
treatment sessions according to allocated group. Since frequent visit would be the burden to
participating patients and cause absences from the trial, we made the criteria on the absence
of participants of each group and the range of dropout. Acupuncture group 1, which have total
12 acupuncture treatment, ought to complete 10 treatment sessions to minimum and acupuncture
group 2 and sham acupuncture group, which have total 8 acupuncture treatment, ought to
complete 6 sessions. Each treatment session of all the allocated group cannot be delayed over
6 days from the previous session.
Outcome measures One health care provider involved in this study will conduct a series of
outcome measures. There will be no separation between primary and secondary outcome since it
is an exploratory pilot study to search independent effectiveness of acupuncture intervention
on atopic dermatitis and secure a dataset for the further study.
SCORAD index Itch VAS EASI score POEM DLQI CES-D STAXI
Investigating biomaterials with blood collection Serum total IgE measurement Serum
cytokine/chemokines measurement Serum cortisol measurement MicroRNA microarray
Statistical Methods Sample size calculation The current trial was established as a pilot
study to investigate the anti-pruritic effects of acupuncture for the patients with atopic
disease. A total of 30 AD patients, 10 in each group, and 20 healthy controls will be
recruited during the study period in regard of 20% dropout rate. Its outcomes will suggest
evidences for feasibility of further large-scale study and sample size calculation.
Statistical analysis A statistician uninvolved in the research team will take charge of the
statistical analysis by using the SPSS 21.0 (IBM SPSS Statistics, New York, USA). Categorical
variables will be provided with percentages and continuous variables will be provided as mean
and standard deviation.
The intervention effectiveness will be analyzed with the changes between the baseline and the
end of treatment period or follow-up period. Data analysis of baseline characteristics
between allocated groups will be compared through a repeated-measures analysis of variance
(ANOVA) test and χ2 test respectively on continuous variables and categorical variables.
The different efficiency according to three times or twice weekly acupuncture treatment will
be analyzed with the changes in itch VAS and SCORAD index by the Mann-Whitney U-test on
continuous variables and χ2 test on categorical variables. The difference on therapeutic
efficiency between verum acupuncture treatment groups and sham acupuncture treatment group
will be investigated in the same way. And these outcome data will be analyzed with 0.1
(two-sided) statistical significance level and the 90% confidence intervals regarding with
the professional advice for the small sample size. For the further study, the difference on
treatment groups and control group will be applied to calculate the number of needed
participants with a set on 0.05 α and 80% power.
Protection of human subjects Ethical approval and registration This study protocol was
approved by the Institutional Review Boards at Kyung Hee University Korean Medicine Hospital
(KOMCIRB-160212-HRBR-004). It will be performed in accordance with the standards of the
International Committee on Harmonization on Good Clinical Practice and the revised version of
the Declaration of Helsinki.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |